On Tuesday, Oragenics Inc. (NYSE:OGEN) said it has completed a key study for its new concussion drug, ONP-002.
What Happened: A recent study shows that the drug successfully targets areas inside the nose connected to the brain, making the drug more likely to reach and treat the brain after a concussion.
In the study, ONP-002 was tested using a nasal spray device. The goal of intranasal casting studies is to identify where the drug lands inside a cast metal anatomical model of the interior nose.
The model is standard for intranasal drug delivery and is accepted by the FDA as a surrogate for the actual nasal passage.
The results showed that the drug spreads well in the nose areas, where it can be quickly absorbed into the brain.
Why It Matters: Oragenics is now preparing to move forward with human testing (Phase 2) in patients who come to the emergency room with a concussion, aiming to give the first dose of the drug within 8 hours of the injury.
In August, Oragenics completed a study that indicates ONP-002 does not cause cardiotoxicity.
A concussion is a mild traumatic brain injury that affects brain function, with an estimated 69 million cases reported annually worldwide.
Long-term symptoms can develop in up to 20% of patients. Currently, there is no pharmaceutical treatment for concussions.
Price Action: OGEN stock closed at $0.39 on Monday.
Read Next:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
